May 07, 2025 12:00pm EDT Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Mar 12, 2025 4:54pm EDT Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Jan 30, 2025 4:00pm EST Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Jan 13, 2025 8:00am EST Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Dec 19, 2024 7:30am EST Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Dec 02, 2024 4:00pm EST First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
